Intranasal delivery of engineered anti-SARS-CoV-2 extracellular vesicles therapeutically represses lung infection and inflammation
Drug Delivery and Translational Research · 2025
DOI: 10.1007/s13346-025-01922-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Delivery and Translational Research, 2025. Verfasst von Adi Idris und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomedicine and Glycomics and School and Pharmacy and Medical Sciences, Griffith University, Southport, QLD, Australia. a2.idris@qut.edu…. Hauptthemen laut MEDLINE: Extracellular Vesicles, SARS-CoV-2, COVID-19, Single-Domain Antibodies. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIMH NIH HHS, Queensland University of Technology.
Abstract (Originalsprache)
Extracellular vesicles (EVs) are amenable to genetic engineering in that EVs can be endowed with surface armaments that can directly bind to target molecules or receptors. We previously developed HEK293 cell-derived EVs that contain a novel fusion tetraspanin protein, CD63, embedded within a highly conserved anti-SARS-CoV-2 nanobody, VHH72. These anti-SARS-CoV-2-enriched EVs bind SARS-CoV-2 spike protein and can functionally neutralize SARS-CoV-2 in vitro. Here, we extend our observations in vivo using EVs derived from neural stem cells (NSCs) and demonstrated the antiviral effectiveness of these direct-acting EVs in the lungs of SARS-CoV-2 infected mice when administered intranasally post-infection. Using NanoString-based immune transcriptomics we showed that these EVs exert mild anti-inflammatory effects on SARS-CoV-2 infected lungs. This is the first demonstration of the effective use of intranasally delivered EVs ladened with anti-SARS-CoV-2 nanobodies in vivo. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biomedicine and Glycomics and School and Pharmacy and Medical Sciences, Griffith University, Southport, QLD, Australia. a2.idris@qut.edu.au.
- Centre for Immunology and Infection Control, School of Biomedical Sciences, Queensland University of Technology, Brisbane, QLD, Australia. a2.idris@qut.edu.au.
- Center for Gene Therapy, City of Hope, Beckman Research Institute and Hematological Malignancy and Stem Cell Transplantation Institute, Duarte, CA, USA.
- Centre for Immunology and Infection Control, School of Biomedical Sciences, Queensland University of Technology, Brisbane, QLD, Australia.
- Institute of Biomedicine and Glycomics and School and Pharmacy and Medical Sciences, Griffith University, Southport, QLD, Australia.
- Centre for Genomics and Personalised Health, School of Biomedical Sciences, Queensland University of Technology, Kelvin Grove, Brisbane, QLD, Australia.
ORCID-Profile: Adi Idris
Förderung
- NIMH NIH HHS
- Queensland University of Technology
Zitieren
APA
Idris, A., Shrivastava, S., Gao, W., Supramaniam, A., Tayyar, Y., West, N. P., Kelly, G., Acharya, D., McMillan, N. A. J., & Morris, K. V. (2025). Intranasal delivery of engineered anti-SARS-CoV-2 extracellular vesicles therapeutically represses lung infection and inflammation. Drug Delivery and Translational Research. https://doi.org/10.1007/s13346-025-01922-9
Vancouver
Idris A, Shrivastava S, Gao W, Supramaniam A, Tayyar Y, West NP, et al. Intranasal delivery of engineered anti-SARS-CoV-2 extracellular vesicles therapeutically represses lung infection and inflammation. Drug Delivery and Translational Research. 2025. doi:10.1007/s13346-025-01922-9
BibTeX
@article{Idris2025,
author = {Idris, Adi and Shrivastava, Surya and Gao, Wenqing and Supramaniam, Aroon and Tayyar, Yaman and West, Nicholas P and Kelly, Gabrielle and Acharya, Dhruba and McMillan, Nigel A J and Morris, Kevin V},
title = {Intranasal delivery of engineered anti-SARS-CoV-2 extracellular vesicles therapeutically represses lung infection and inflammation},
journal = {Drug Delivery and Translational Research},
year = {2025},
doi = {10.1007/s13346-025-01922-9}
}
EUVIMED